Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 572 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-Alcoholic Steatohepatitis (NASH) Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

NAFLD Clinical Care Pathway

NCT06671886
View directory record Official record
Conditions
NAFLD, MASLD
Interventions
E-trigger
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 13, 2026, 7:05 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients

NCT02194894
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Acetaminophen
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Not applicable Interventional

The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology

NCT05370053
View directory record Official record
Conditions
Fatty Liver, NAFLD
Interventions
ELF Test
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

NCT03213145
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
intraconazole, Rifampin, EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Role of Exenatide in NASH-a Pilot Study

NCT00650546
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Exenatide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Indianapolis, Indiana • Kansas City, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 13, 2026, 7:05 PM EDT
Terminated Phase 2 Interventional Results available

Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)

NCT01244503
View directory record Official record
Conditions
Metabolic Syndrome, Nonalcoholic Fatty Liver Disease
Interventions
Sodium Octanoate Breath Test
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Not applicable Interventional Results available

Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

NCT03696797
View directory record Official record
Conditions
Iron, Diabetes, Nonalcoholic Fatty Liver
Interventions
Blood Donation, Sham Blood Donation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 2 Interventional Results available

6-week Safety and PD Study in Adults With NAFLD

NCT03256526
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Placebo, PF-06835919 Low Dose, PF-06835919 High Dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Los Angeles, California • DeLand, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Not applicable Interventional

Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease

NCT01556113
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease, Steatohepatitis, Hypertriglyceridemia, Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1
Interventions
Omega diet
Other
Lead sponsor
Yale University
Other
Eligibility
10 Years to 19 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 1 Interventional

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

NCT06947304
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Miricorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 13, 2026, 7:05 PM EDT
Active, not recruiting No phase listed Observational

Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

NCT05507151
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Endoscopic Sleeve Gastroplasty
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 13, 2026, 7:05 PM EDT
Active, not recruiting No phase listed Observational

Nonalcoholic Fatty Liver Disease in HIV Database

NCT05023044
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 13, 2026, 7:05 PM EDT
Terminated No phase listed Observational

The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients

NCT04284371
View directory record Official record
Conditions
Steatohepatitis, Nonalcoholic, Hemosiderosis, Overweight Adolescents, Obesity, Childhood, Liver Steatosis
Interventions
Not listed
Lead sponsor
The Geneva Foundation
Other
Eligibility
10 Years to 17 Years
Enrollment
150 participants
Timeline
2016 – 2021
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

NCT05117489
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Miricorilant 150 mg, Miricorilant 100 mg, Miricorilant 50 mg, Miricorilant 10 mg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 2 Interventional Results available

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

NCT03205150
View directory record Official record
Conditions
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Baton Rouge, Louisiana • St Louis, Missouri • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 4 Interventional Results available

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

NCT01006889
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Exenatide
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 13, 2026, 7:05 PM EDT
Recruiting Phase 2 Interventional

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

NCT05519475
View directory record Official record
Conditions
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions
ALN-HSD, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
61
States / cities
Flagstaff, Arizona • Peoria, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 7:05 PM EDT
Recruiting Phase 4 Interventional

Quantifying Hepatic Mitochondrial Fluxes in Humans

NCT05305287
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 2 Interventional Results available

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

NCT04321031
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Interventions
Placebo, PF-06865571, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
184
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Adults Evaluating PF-07202954

NCT04857437
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Interventions
PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Non-cirrhotic NASH With Fibrosis

NCT05638737
View directory record Official record
Conditions
Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions
AZD4831, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Chandler, Arizona • Tucson, Arizona • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 13, 2026, 7:05 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach

NCT04841057
View directory record Official record
Conditions
Obesity, Morbid, Metabolic Syndrome, NASH - Nonalcoholic Steatohepatitis
Interventions
50 cm BP limb length, 100 cm BP limb length, 150 cm BP limb length
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 80 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 2 Interventional Results available

Pentoxifylline in Patients With Nonalcoholic Steatohepatitis

NCT00590161
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
pentoxifylline (PTX), placebo
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 13, 2026, 7:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NCT04048135
View directory record Official record
Conditions
NASH
Interventions
Pegozafermin, Placebo
Drug · Other
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 13, 2026, 7:05 PM EDT